###### Strengths and limitations of this study

-   We systematically selected and collected the available literature on the role of sex in adherence to antihypertensives.

-   Potential interaction between sex and other variables was explored by means of various analyses.

-   Although the systematic revision focused on two metrics for measuring adherence to antihypertensives (ie, self-report and pharmacy refill metric), more technological and recent methods for the adherence evaluation were not included in this investigation.

Introduction {#s1}
============

Randomised clinical trials have shown that hypertension is a reversible risk factor, that is, that a reduction in elevated blood pressure (BP) values by treatment reduces the risk of fatal and non-fatal cardiovascular (CV) events.[@R1] However, effective BP reductions are rare in patients with hypertension who are thus characterised by a high prevalence of uncontrolled BP[@R2] and an increased incidence of CV events,[@R5] keeping hypertension as one of the major risk factors for CV disease, which is leading cause of death.[@R6]

Although several factors are involved,[@R7] a consensus exists that the poor worldwide rate of BP control is largely due to poor adherence to the treatment regimen.[@R8] In general, adherence may be defined as the extent to which patients follow treatment prescribed by their healthcare providers.[@R18] Adherence to antihypertensive (AHT) medications is an imperative issue which can be directly linked with the management of chronic diseases, such as hypertension.[@R19] In particular, adherence to AHT drug therapy, considered an important factor to control BP, 1 year after initiation is typically reported at \<50%.[@R20] Indeed, non-adherence is an additional risk factor of fatal CV events in real-life setting.[@R21]

Many factors have been shown to affect adherence to AHT treatment recommendations[@R22]: (1) demographic aspects, such as age,[@R25] ethnicity, marital status, educational level, socioeconomic status[@R28]; (2) clinical factors, like cognitive problems, depression, complicated therapeutic regimens[@R28] (eg, number of doses, concurrent medications and changes in AHT treatment)[@R29]; (3) knowledge of patient about hypertension and AHT treatment,[@R31] perception of the health risk related to the disease[@R32] and the relationship between patient and healthcare provider.[@R36]

Among these, the question of whether sex may be considered a predictor of adherence has long been debated. In fact, differences between men and women in attitudes, beliefs and motivation towards health issues[@R37] might possibly influence adherence to health recommendations, particularly to dispensed drug therapies. Notwithstanding the wide range of published literature on this issue, conflicting findings have been reported about adherence to AHT and sex.[@R39] Several studies have found that women have higher levels of hypertension awareness than men,[@R41] which tend to increase with age.[@R43] Thus, women may be more motivated to adhere because they understand the risk of non-adherence[@R44] and get better use of healthcare services.[@R45] In addition, women may receive less aggressive treatment after the occurrence of a CV event,[@R46] which could promote their better adherence to medication. Finally, it has been reported that women had better adherence to other chronic drug therapies, such as those for treatment of depression[@R48] and diabetes mellitus.[@R51] Inconsistently, however, a recent meta-analysis reported higher refill rate of statins in men than women.[@R52]

Although there are several self-report instruments to assess drug adherence (eg, Hill-Bone Compliance Scale,[@R53] the Medication adherence rating scale[@R54] and the Hypertension Self-Care Activity Level Effects[@R55]), the Morisky Medication Adherence Scale (MMAS)[@R56] is the most applied. MMAS is an adherence-screening tool based on the complexity of assessing adherence in hypertension. The validated questionnaire is composed of four or eight items[@R57] about past use of AHTs with a cut-off value of MMAS mean score of respectively three or six for labelling patients as adherent or not.

To the best of our knowledge, there is only one systematic review focused on this research topic that reported better adherence to AHT therapy in women than men.[@R58] However, because these findings were generated by assembling studies that investigated adherence by means of the MMAS questionnaire, some caution should be adopted due to the questionable between sex reproducibility of answers to medication-taking questions.[@R59]

Therefore, we decided to extend the systematic review conducted by Abegaz *et al*[@R58] to investigations that studied adherence by prescription-refill data, that is, the most used data source for assessing the adherence of large population. Two common measures could be used to quantify adherence by means of prescription refill data: the medication possession ratio (MPR) and the proportion of days covered (PDC).[@R60] These two measurements are essentially defined by the number of doses dispensed respect to the observation time and patients with MPR or PDC greater than 80% are classified as adherent.[@R62]

With these premises, we performed a systematic review and meta-analysis of available observational studies comparing adherence to AHT medication in men and women, in accordance with the Preferred Reporting Items for Systematic Reviews and Meta-Analyses statement[@R63] ([online supplementary table S1](#SP1){ref-type="supplementary-material"}). Because pre-existing data do not allow of making an initial hypothesis on the possible direction of the sex-adherence association, our synthesis of current knowledge about the issue must be seen as exploratory rather than hypothesis testing.
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Materials and methods {#s2}
=====================

Search strategy and study selection {#s2-1}
-----------------------------------

We performed a PubMed, CINAHL, PsycINFO, Web of Science and Google Scholar search for observational studies published up to January 2020 that reported data on adherence to AHT drugs in men and women. Studies were included in our review if they assessed treatment adherence in clinical practice and by means of self-reported or pharmacy refill methods. In the main analysis, no inclusion/exclusion criterion was applied regarding the length of follow-up in which drug adherence was assessed. Search strategy included keywords and/or corresponding MeSH terms related to adherence, AHT medication and sex. Full details on strategy adopted are reported in the [online supplementary table S2](#SP1){ref-type="supplementary-material"}.

The search was limited to studies published in English language and articles were included if they reported quantitative data on AHT adherence in men and women. When data were published more than once, the most recent and complete paper was selected. Papers, which did not report original findings (ie, letters, case report, systematic review and meta-analysis) or selected a population taking AHT drugs for conditions different from hypertension (eg, myocardial infarction or heart failure) were excluded. Moreover, a hand-checking search was performed in order to identify additional relevant studies. The search was designated by GC and validated by all the authors, whereas extraction of articles was performed by one of the authors (AB) and independently verified by a second author (FR) to determine the eligibility of each article for inclusion. Discrepancies between readers were resolved in conference.

Data collection {#s2-2}
---------------

For each included study, we extracted details on publication year, country where the study was conducted, characteristics of the investigated persons (eg, mean age, number of women and men), employed AHT agents, adjustment and stratification variables, adherence in men and women, and OR, or other association measures, with 95% CI or p value, for the association between sex and adherence. Moreover, we evaluated the quality of the eligible studies according to the Newcastle Ottawa scale ([online supplementary table S3](#SP1){ref-type="supplementary-material"})[@R64] and more than five points identified high-quality studies. In addition, information about the metric adopted for measuring adherence was also recorded. In particular, studies were classified according to whether self-report or pharmacy refill prescription-based methods were adopted. The former ones were based on 4-item or 8-item MMAS (MMAS-4 and MMAS-8, respectively), while the latter ones concerned the MPR or the PDC.[@R65]

Statistical analysis {#s2-3}
--------------------

The measure of interest was the summary OR (OR~s~) that evaluated the association between AHT adherence and sex, using men as reference. Unless otherwise specified,[@R66] a patient with MMAS-4 ≥3, MMAS-8 ≥6[@R67] or MPR/PDC ≥80% was considered to be on good adherence. Where possible, we pooled adjusted estimates from the original studies; raw data and computed unadjusted ORs were used otherwise. Estimates were summarised if at least three studies reported the association of interest.

Heterogeneity between study-specific estimates was tested using X^2^ statistics[@R69] and measured with the I^2^ index (a measure of the percentage variation across the studies caused by heterogeneity).[@R70] To take into account differences in sample characteristics, measurement and other factors, we pooled the original estimates by fitting the DerSimonian and Laird random-effects model.[@R71] Influence analysis was conducted by omitting one study at a time in order to identify to what extent the results were influenced by a single study.

Other than classical meta-analysis, meta-regression models were performed for estimating the effect of above-reported covariates (ie, method for collecting adherence data, incident/prevalent users, adjusted/unadjusted estimates, geographical area) on the log (OR~s~). The regression models were fitted including one covariate at a time.

To explore the interaction between sex and other variables on the propensity of being adherent, subgroup analyses were carried out. Studies were stratified according to known determinants of adherence, that is, age, prevention status (primary vs secondary) and drug users (incident vs prevalent users). Medication therapy was considered for primary prevention if patients with a pre-existing CV disease were excluded from the study; conversely, the drug use was considered for secondary prevention. In addition, patients were classified as incident users if long-term medication takers were excluded from the analysis; otherwise, the study was considered to be performed among prevalent users.

Furthermore, subgroup analyses were performed according to the length of follow-up, the geographical area where the study was carried out, and whether the estimates were adjusted or not.

All tests were considered statistically significant for p values less than 0.05. The analyses and the correspondent graphical visualisation of forest and funnel plots were respectively performed by using RevMan V.5.3 (Nordic Cochrane Center) and STATA Software Program V.13.1 (STATA).

Patient and public involvement {#s2-4}
------------------------------

No patients were involved in the development of the research question, outcome measures, design, study implementation, dissemination of the results of the research to the study participants or interpretation of the results.

Results {#s3}
=======

Study selection and characteristics {#s3-1}
-----------------------------------

As shown in [figure 1](#F1){ref-type="fig"}, 12 849 papers were first identified. After screening their abstracts and titles, 11 971 articles were excluded mainly because they were (1) no related to the issue, (2) duplicates, (3) letters, case report, review or meta-analysis. Among the remaining 878 articles which were assessed for full-text review, 802 were excluded because not written in English language (n=51), analysed patients not of interest (25), not found (12), not reporting quantitative estimates of interest (169), data were published more than once (31), unrelated to the issue (514). Other than the 76 papers thus selected,[@R28] six additional papers were found through hand searching of relevant papers.[@R40]

![Flow diagram of the selection of studies regarding self-reported and refill rates used to measure adherence to AHT. AHT, antihypertensive.](bmjopen-2019-036418f01){#F1}

Information about the main characteristics of the 82 papers agreeing with the inclusion criteria and included in the current meta-analysis are shown in [table 1](#T1){ref-type="table"}. Adherence to AHT was measured with MPR and PDC metrics from 16 and 17 studies respectively, while 49 papers applied the MMAS-4 or MMAS-8 scales. Overall, 34 670 674 hypertensive patients (15 517 457 men and 18 537 599 women) were included into these studies. For the most part of them, adherence was measured with MPR (more than 30 million), less with PDC (about 2 million), while MMAS-4 and MMAS-8 scales were used for 27 160 and 12 062 patients, respectively. Moreover, two articles were assigned to the low-quality category[@R86] although there was variability among the assigned quality scores.

###### 

Characteristics of the studies comparing adherence to AHT drugs between men and women

  ------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  First author publication year, country (reference)   Age range              Sample size m/f           Exposure                                                                                                                                                                                                               OR (95% CI)                       Controlled variables/notes                                                                                                                                                                                                               Follow-up    Quality
  ---------------------------------------------------- ---------------------- ------------------------- ---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------- --------------------------------- ---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------- ------------ ---------
  Adherence to AHT inUsers of AHTMPR                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                   

  Alfian 2019, the Netherlands[@R130]                  ≥40                    5468\                     AHT (diuretic, BB, CCB, agent acting on the renin-angiotensin system)                                                                                                                                                  1.10 (0.93 to 1.31)               Unadjusted estimates                                                                                                                                                                                                                     1 year       High
                                                                              3068/2400                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                

  Calderón-Larrañaga 2016, Spain[@R100]                ≥18                    113 397\                  AHT (ACEi, ARB, BB, CCB, thiazide diuretics)                                                                                                                                                                           0.89 (0.87 to 0.92)               Age, nationality, residence location, blood pressure level, mental comorbidity, health status, CV risk factors, polypharmacy, visit to GP, different specialties visited                                                                 1 year       High
                                                                              50242/63155                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                              

  Friedman 2010, America[@R101]                        ≥66                    207 473\                  AHT (ACEi, ARB, BB, CCB, thiazide and thiazide-like diuretics, and combination agent)                                                                                                                                  1.12 (1.06 to 1.18)               Age, calendar year, therapeutic class, illness severity, socioeconomic status, residence location, medical service type                                                                                                                  2 years      High
                                                                              86308/121165                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                             

  Holmes 2012, America[@R72]                           ≥66                    168 522\                  AHT (ACEi, alpha-blockers, ARB, BB, CCB, diuretics, vasodilators)                                                                                                                                                      1.00 (0.94 to 1.02)               Age, ethnicity, socioeconomic status, residence location, education, comorbidities, concomitant comedications                                                                                                                            1 year       High
                                                                              51580/116942                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                             

  Inkster 2006, Scotland[@R102]                        40--79                 511\                      AHT                                                                                                                                                                                                                    0.87 (0.53 to 1.44)               n.a.                                                                                                                                                                                                                                     2 years      High
                                                                              242/269                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                  

  Ishisaka 2012, America[@R103]                        ≥18                    51 772\                   AHT (ACEi, alpha one adrenergic antagonists, alpha two adrenergic agonists, ARB, AHT combinations, BB, CCB, other AHT medication (hydralazine, reserpine, minoxidil), thiazide diuretics, and diuretic combinations)   1.00 (0.97 to 1.04)               Age, ethnicity, CDS                                                                                                                                                                                                                      3 years      High
                                                                              22397/29375                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                              

  Lee 2013, Taiwan[@R128]                              ≥30                    78 558\                   AHT (alpha-blockers, ACEi, ARB, BB, CCB, other)                                                                                                                                                                        0.92 (0.89 to 0.95)               Age, socioeconomic status, CCI, medical service type, concomitant comedications, public assistance                                                                                                                                       1 year       High
                                                                              39047/39511                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                              

  Manteuffel 2014, America[@R104]                      ≥18                    29 470 455\               AHT                                                                                                                                                                                                                    0.989746 (0.988274 to 0.991221)   Unadjusted estimates                                                                                                                                                                                                                     1 year       High
                                                                              13458395/16012060                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                        

  Morris 2006, America[@R28]                           ≥18                    492\                      AHT (ACEi, alpha receptor antagonists, angiotensin II receptor antagonists, beta adrenergic receptor antagonists, clonidine, diuretics, vasodilators)                                                                  0.77 (0.50 to 1.18)               Unadjusted estimates                                                                                                                                                                                                                     1 year       High
                                                                              132/360                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                  

  Muntner 2013, America[@R145]                         ≥65                    1391\                     AHT (ACEi, ARB, BB, CCB, diuretics)                                                                                                                                                                                    1.00 (0.79 to 1.25)               Unadjusted estimates                                                                                                                                                                                                                     1 year       High
                                                                              553/838                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                  

  Park 2008, South Korea[@R73]                         ≥20                    2455193 1028724/1426469   AHT                                                                                                                                                                                                                    0.97 (0.95 to 0.99)               Age, disability, comorbidities, treatment duration, socioeconomic status, residence location, concomitant comedications, medical service type                                                                                            1 year       High

  Shah 2007, America[@R142]                            ≥18                    708\                      AHT                                                                                                                                                                                                                    0.96 (0.71 to 1.29)               Unadjusted estimates                                                                                                                                                                                                                     1 year       High
                                                                              378/330                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                  

  Taira 2007, Hawaii[@R105]                            ≥18                    28 395\                   AHT (ACEi, ARB, BB, CCB, thiazide type diuretics)                                                                                                                                                                      1.00 (0.96 to 1.05)               Age, illness severity, type of medical programme, therapeutic class, comorbidities, sociodemographic characteristics, education, physician characteristics                                                                               1 year       High
                                                                              13346/15049                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                              

  van Dijk 2007, the Netherlands[@R106]                n.a.                   12 110\                   AHT (ACEi, Angiotensin II receptor antagonists, BB, diuretics, other)                                                                                                                                                  0.93 (0.81 to 1.05)               Sociodemographic characteristics, concomitant comedications, comorbidities, health status                                                                                                                                                1 year       High
                                                                              5156/6954                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                

  Van Wijk 2006, the Netherlands[@R99]                 Mean age 60.22±14.19   1232\                     AHT (ACEi, Angiotensin II receptor antagonists, BB, CCB, diuretic, other)                                                                                                                                              0.97 (0.71 to 1.34)               Unadjusted estimates                                                                                                                                                                                                                     1 year       High
                                                                              595/637                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                  

  Wong 2010, China[@R107]                              ≥18                    83 884\                   AHT (BB, CCB, drugs acting on RAS and others (including alfa blockers, potassium sparing and other diuretics, vasodilators and combination treatement), thiazide diuretics)                                            1.19 (1.13 to 1.25)               Age, sociodemographic characteristics, socioeconomic status, medical service type, residence location, different specialties visited, Visit to GP, comorbidities, AHT drug class                                                         3 years      High
                                                                              35902/47982                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                              

  **PDC**                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                              

  Chang 2019, America[@R131]                           ≥18                    2927\                     (ACEi, ARB, renin-angiotensin system antagonists, BB, CCB, diuretics, other AHTs)                                                                                                                                      0.87 (0.74 to 1.02)               Unadjusted estimates                                                                                                                                                                                                                     1 year       High
                                                                              1452/1476                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                

  Couto 2014, America[@R108]                           ≥18                    659 553\                  AHT (ACEi, direct renin inhibitors and angiotensin II-receptor antagonists, or any combination product including one or more of these classes)                                                                         0.85 (0.83 to 0.86)               Age, nationality, socioeconomic status                                                                                                                                                                                                   1 year       High
                                                                              369372/290181                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                            

  Cyrus 2019, America[@R132]                           22--64                 1573\                     AHT (diuretics, BB, ACEi, angiotensin II receptor blockers, CCB, alpha blockers, alpha-2 receptor agonists, central agonists, peripheral adrenergic inhibitors, vasodilators, and renin inhibitors)                    1.11 (0.89 to 1.39)               Age, CCI, comorbidities, concomitant comedications, ethnicity, residence, Visit to GP                                                                                                                                                    1 year       High
                                                                              829/744                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                  

  Degli Esposti 2010, Italy[@R109]                     ≥18                    94 947\                   AHT (ACEi, ARB, BB, CCB, diuretics)                                                                                                                                                                                    1.35 (1.31 to 1.39)               Age, calendar year, prior medications, concomitant comedications                                                                                                                                                                         1 year       High
                                                                              40771/54176                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                              

  Di Martino 2008, Italy[@R66]                         ≥18                    7626\                     AHT                                                                                                                                                                                                                    1.45 (1.30 to 1.62)               Age, start of treatment, diabetes, hypertension/renal disease, concomitant comedications                                                                                                                                                 1 year       High
                                                                              3222/4404                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                

  Hedna 2015, Sweden[@R46]                             n.a.                   867\                      AHT (ACEi, combination ACEi and diuretics, ARB, combination ARB and diuretics, anti-adrenergic, BB, CCB, diuretics)                                                                                                    1.02 (0.74 to 1.40)               AHT drug class, age, education, socioeconomic status, Diagnosis Related Group weight, CV risk factors                                                                                                                                    2 years      High
                                                                              412/455                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                  

  Iyengar 2014, America[@R147]                         ≥65                    615 618\                  AHT                                                                                                                                                                                                                    1.06 (1.05 to 1.07)               n.a.                                                                                                                                                                                                                                     1 year       High
                                                                              n.a.                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                     

  Williams 2018, America[@R74]                         ≥65                    2122\                     AHT                                                                                                                                                                                                                    0.93 (0.77 to 1.13)               Unadjusted estimates                                                                                                                                                                                                                     1 year       High
                                                                              866/1256                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                 

  Lauffenburger 2017, America[@R110]                   ≥18                    462 227\                  AHT (ACEi, ARB, BB, CCB, diuretics, thiazide, other)                                                                                                                                                                   RR 0.89\                          Age, residence location, comorbidities, diabetes, Prior hospitalisation, public assistance                                                                                                                                               1 year       High
                                                                              222912/239315                                                                                                                                                                                                                                    (0.88 to 0.90)                                                                                                                                                                                                                                                                          

  Mazzaglia 2009, Italy[@R144]                         ≥35                    18 806\                   AHT                                                                                                                                                                                                                    1.13 (1.07 to 1.21)               Unadjusted estimates                                                                                                                                                                                                                     6 months     High
                                                                              7835/10971                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                               

  Nguyen 2017, Vietnam[@R75]                           35--64                 315\                      AHT                                                                                                                                                                                                                    1.53 (0.96 to 2.45)               Age, ethnicity, CV risk factors                                                                                                                                                                                                          1 year       High
                                                                              171/144                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                  

  Perseguer-Torregrosa 2014, Spain[@R76]               ≥50                    419\                      AHT                                                                                                                                                                                                                    1.46 (0.95 to 1.97)               Age, CV risk factors, history of hypertension, AHT drug class, concomitant comedications, BMI, diabetes, dyslipidaemia, quality of life survey                                                                                           \<2 months   High
                                                                              184/235                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                  

  Rea 2020, Italy[@R133]                               40--80                 60 526\                   AHT (diuretics, ACEIs, ARBs, BB, CCB, alpha-blockers)                                                                                                                                                                  0.88 (0.32 to 2.47)               Age, comorbidities, concomitant comedications, multisource comorbidity score, start of treatment                                                                                                                                         1 year       High
                                                                              30860/29666                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                              

  Simon-Tuval 2016, Israel[@R111]                      Mean age 64.58±8.94    1582\                     AHT (ACEI, ARB, BB, CCB)                                                                                                                                                                                               1.27 (1.03 to 1.58)               Unadjusted estimates                                                                                                                                                                                                                     4 years      High
                                                                              1086/496                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                 

  Walsh 2019, Ireland[@R134]                           ≥50                    1431\                     AHT (diuretics, BB, CCB, Agents acting on the renin angiotensin system)                                                                                                                                                1.08 (0.85 to 1.36)               Unadjusted estimates                                                                                                                                                                                                                     1 year       High
                                                                              645/786                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                  

  Wang 2019, America[@R148]                            ≥65                    10 836\                   AHT                                                                                                                                                                                                                    0.77 (0.70 to 0.85)               Age, start of treatment, nationality, comorbidities, diabetes, prior hospitalisation, type of medical programme, previous use of AHT                                                                                                     1 year       High
                                                                              5836/5000                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                

  Wong 2015, China[@R148]                              Mean age 58.65±17.32   203 258\                  AHT (ACEi, alfa blockers, BB, CCB, thiazide diuretics)                                                                                                                                                                 0.87 (0.85 to 0.89)               Age, public assistance, medical service type, start of treatment, residence location, treatment duration                                                                                                                                 1 year       High
                                                                              89725/113533                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                             

  **4-item Morisky Medication Adherence Scale**                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                        

  Alhaddad 2016, Lebanon and Jordan[@R77]              \>21                   1470\                     AHT                                                                                                                                                                                                                    1.04 (0.84 to 1.29)               Unadjusted estimates                                                                                                                                                                                                                                  High
                                                                              842/628                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                  

  Ambaw 2012, Ethiopia[@R113]                          ≥18                    384\                      AHT                                                                                                                                                                                                                    2.08 (1.22 to 3.57)               Residence location, marital status, religion, education, socioeconomic status, comorbidities, blood pressure level, distance from the hospital, dosing frequency, sociodemographic characteristics, AHT drug class, GP characteristics                High
                                                                              142/242                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                  

  Arshad 2015, Pakistan[@R114]                         Mean age 58.81±12.26   106\                      AHT                                                                                                                                                                                                                    0.91 (0.40 to 2.11)               Unadjusted estimates                                                                                                                                                                                                                                  Low
                                                                              53/53                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                    

  Bader 2015, Northern United Arab Emirates[@R115]     ≥18                    250\                      AHT                                                                                                                                                                                                                    1.91 (1.15 to 3.18)               Unadjusted estimates                                                                                                                                                                                                                                  High
                                                                              134/116                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                  

  Cuffee 2013, America[@R116]                          ≥19                    780\                      AHT                                                                                                                                                                                                                    0.72 (0.52 to 0.98)               Age, sex, education, socioeconomic, Hall Trust Scale                                                                                                                                                                                                  High
                                                                              314/466                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                  

  Demoner 2012, America[@R117]                         \>18                   150\                      AHT                                                                                                                                                                                                                    1.81 (0.86 to 3.83)               Unadjusted estimates                                                                                                                                                                                                                                  High
                                                                              48/102                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                   

  Dosse 2009, America[@R118]                           Mean age 61.01±9.46    68\                       AHT                                                                                                                                                                                                                    1.11 (0.25 to 4.88)               Unadjusted estimates                                                                                                                                                                                                                                  High
                                                                              24/44                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                    

  Grégoire 2006, America[@R78]                         ≥18                    509\                      AHT (ACEi, ARB, CCB)                                                                                                                                                                                                   0.81 (0.53 to 1.22)               Unadjusted estimates                                                                                                                                                                                                                                  High
                                                                              225/284                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                  

  Hashmi 2007, Pakistan[@R79]                          ≥18                    438\                      AHT                                                                                                                                                                                                                    0.93 (0.60 to 1.46)               Unadjusted estimates                                                                                                                                                                                                                                  High
                                                                              199/239                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                  

  Khan 2014, America[@R80]                             18--60                 200\                      AHT                                                                                                                                                                                                                    0.49 (0.23 to 1.05)               Unadjusted estimates                                                                                                                                                                                                                                  High
                                                                              77/123                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                   

  Li 2006, America[@R81]                               ≥18                    200\                      AHT                                                                                                                                                                                                                    1.45 (0.76 to 2.75)               Unadjusted estimates                                                                                                                                                                                                                                  High
                                                                              100/100                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                  

  Lo 2016, China[@R119]                                ≥65                    195\                      AHT                                                                                                                                                                                                                    0.96 (0.47 to 1.92)               Unadjusted estimates                                                                                                                                                                                                                                  High
                                                                              40/155                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                   

  Lulebo 2015, Democratic Republic of Congo[@R82]      \>18                   395\                      AHT                                                                                                                                                                                                                    0.80 (0.50 to 1.30)               Unadjusted estimates                                                                                                                                                                                                                                  High
                                                                              95/300                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                   

  Morrison 2015, Europe[@R83]                          ≥18                    2595\                     AHT                                                                                                                                                                                                                    1.22 (1.01 to 1.47)               Age, education, marital status, socioeconomic status, concomitant comedications, dosing frequency, illness consequences                                                                                                                               High
                                                                              1334/1261                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                

  Park 2013, South Korea[@R84]                         ≥65                    241\                      AHT                                                                                                                                                                                                                    0.67 (0.40 to 1.14)               Unadjusted estimates                                                                                                                                                                                                                                  High
                                                                              144/97                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                   

  Stavropoulou 2012, Greece[@R85]                      Mean age 61            735\                      AHT                                                                                                                                                                                                                    1.08 (0.83 to 1.39)               Age, education, socioeconomic status, illness consequences                                                                                                                                                                                            High
                                                                              294/441                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                  

  Tibebu 2017, Ethiopia[@R40]                          ≥18                    404\                      AHT                                                                                                                                                                                                                    2.18 (1.33 to 3.58)               Age, marital status, education, socioeconomic, concomitant comedications, sociodemographic characteristics                                                                                                                                            High
                                                                              210/194                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                  

  Turner 2009, America[@R86]                           \>70                   202\                      AHT                                                                                                                                                                                                                    1.26 (0.63 to 2.50)               Unadjusted estimates                                                                                                                                                                                                                                  Low
                                                                              69/133                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                   

  Usman 2019, Nigeria[@R135]                           ≥18                    237\                      AHT                                                                                                                                                                                                                    0.32 (0.18 to 0.56)               Unadjusted estimates                                                                                                                                                                                                                                  High
                                                                              76/161                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                   

  Wagner 2012, America[@R97]                           ≥18                    16 474\                   AHT                                                                                                                                                                                                                    1.97 (1.85 to 2.11)               Unadjusted estimates                                                                                                                                                                                                                                  High
                                                                              8402/8072                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                

  Wang 2014, Australia[@R96]                           ≥65                    382\                      AHT                                                                                                                                                                                                                    0.99 (0.60 to 1.63)               Age, marital status, education, comorbidities, previous use of AHT, public assistance                                                                                                                                                                 High
                                                                              185/197                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                  

  Yang 2016, China[@R120]                              ≥18                    745\                      AHT                                                                                                                                                                                                                    0.75 (0.56 to 1.01)               Unadjusted estimates                                                                                                                                                                                                                                  High
                                                                              345/400                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                  

  **8-items Morisky Medication Adherence Scale**                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                       

  Adidja 2018, Cameroon[@R87]                          ≥21                    183\                      AHT                                                                                                                                                                                                                    1.10 (0.40 to 2.60)               Age, socioeconomic status, illness consequences, history of hypertension, previous use of AHT                                                                                                                                                         High
                                                                              65/118                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                   

  Al-Ramahi Rowa' 2015, Palestine[@R88]                ≥18                    450\                      AHT                                                                                                                                                                                                                    1.01 (0.69 to 1.46)               Unadjusted estimates                                                                                                                                                                                                                                  High
                                                                              197/253                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                  

  Alkhamis 2019, Saudi Arabia[@R136]                   ≥18                    372\                      AHT                                                                                                                                                                                                                    1.49 (0.97 to 2.27)               Unadjusted estimates                                                                                                                                                                                                                                  High
                                                                              231/141                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                  

  Hacıhasanoğlu Aşılar 2014, Turkey[@R121]             ≥18                    196\                      AHT                                                                                                                                                                                                                    1.18 (0.65 to 2.11)               Unadjusted estimates                                                                                                                                                                                                                                  High
                                                                              77/119                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                   

  Behnood-Rod 2016, Iran[@R122]                        Mean age 60.3±10       280\                      AHT                                                                                                                                                                                                                    1.03 (0.64 to 1.65)               Unadjusted estimates                                                                                                                                                                                                                                  High
                                                                              118/162                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                  

  Berhe 2017, Ethiopia[@R123]                          ≥18                    925\                      AHT                                                                                                                                                                                                                    1.04 (0.81 to 1.36)               Unadjusted estimates                                                                                                                                                                                                                                  High
                                                                              355/570                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                  

  Cummings 2016, America[@R124]                        Mean age 57.3±12.8     495\                      AHT                                                                                                                                                                                                                    0.96 (0.65 to 1.40)               Unadjusted estimates                                                                                                                                                                                                                                  High
                                                                              161/334                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                  

  Esmaeili 2016, Iran[@R94]                            Mean age 65.02±8.88    422\                      AHT                                                                                                                                                                                                                    1.44 (0.93 to 2.23)               Unadjusted estimates                                                                                                                                                                                                                                  High
                                                                              123/299                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                  

  Fortuna 2018, America[@R89]                          ≥18                    2128\                     AHT                                                                                                                                                                                                                    0.99 (0.80 to 1.20)               Age, ethnicity, public assistance, information about treatment                                                                                                                                                                                        High
                                                                              860/1268                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                 

  Gavrilova 2019, Latvia[@R137]                        ≥18                    171\                      AHT (beta adrenoceptor blockers, ARB, aldosterone antagonists, CCB, ACEi, diuretics)                                                                                                                                   1.90 (0.95 to 3.83)               Unadjusted estimates                                                                                                                                                                                                                                  High
                                                                              43/128                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                   

  Gowda 2019, India[@R138]                             ≥29                    150\                      AHT                                                                                                                                                                                                                    0.41 (0.14 to 1.18)               Unadjusted estimates                                                                                                                                                                                                                                  High
                                                                              96/54                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                    

  Han 2015, Myanmar[@R98]                              ≥30                    216\                      AHT (ACEi, ARB, BB, CCB, other)                                                                                                                                                                                        0.54 (0.30 to 0.99)               Age, education, socioeconomic status, comorbidities, history of hypertension, illness consequences, sociodemographic characteristics                                                                                                                  High
                                                                              89/127                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                   

  Hyre 2007, America[@R125]                            ≥18                    295\                      AHT                                                                                                                                                                                                                    1.29 (0.70 to 2.36)               Unadjusted estimates                                                                                                                                                                                                                                  High
                                                                              195/100                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                  

  Holt 2013, America[@R90]                             ≥65                    2194\                     AHT                                                                                                                                                                                                                    0.81 (0.67 to 0.98)               Unadjusted estimates                                                                                                                                                                                                                                  High
                                                                              911/1283                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                 

  Hou 2016, China[@R143]                               ≥60                    585\                      AHT                                                                                                                                                                                                                    0.93 (0.65 to 1.32)               Unadjusted estimates                                                                                                                                                                                                                                  High
                                                                              353/232                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                  

  Mahmood 2020, Pakistan[@R139]                        ≥18                    741\                      AHT                                                                                                                                                                                                                    0.88 (0.24 to 3.26)               Unadjusted estimates                                                                                                                                                                                                                                  High
                                                                              389/352                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                  

  Kang 2015, China[@R91]                               ≥18                    2445\                     AHT                                                                                                                                                                                                                    0.84 (0.70 to 1.02)               Age, education, socioeconomic status, marital status, sociodemographic characteristics, illness consequences, concomitant comedications, comorbidities                                                                                                High
                                                                              1074/1371                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                

  Kumar 2014, India[@R129]                             \>18                   120\                      AHT                                                                                                                                                                                                                    0.77 (0.36 to 1.62)               Unadjusted estimates                                                                                                                                                                                                                                  High
                                                                              76/44                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                    

  Nabi 2019, Bangladesh[@R140]                         n.a.                   100\                      AHT                                                                                                                                                                                                                    3.27 (1.42 to 7.50)               Unadjusted estimates                                                                                                                                                                                                                                  High
                                                                              57/43                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                    

  Okeke 2019, Nigeria[@R141]                           n.a.                   421\                      AHT                                                                                                                                                                                                                    1.42 (0.82 to 2.48)               Unadjusted estimates                                                                                                                                                                                                                                  High
                                                                              210/211                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                  

  Okello 2016, Uganda[@R95]                            n.a.                   329\                      AHT                                                                                                                                                                                                                    1.21 (0.41 to 1.59)               Age, education, marital status, distance from the clinic, concomitant comedications                                                                                                                                                                   High
                                                                              101/228                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                  

  Jankowska-Polanska 2017, Poland[@R126]               \>18                   620\                      AHT                                                                                                                                                                                                                    1.47 (1.04 to 2.07)               Unadjusted estimates                                                                                                                                                                                                                                  High
                                                                              287/333                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                  

  Rahmawati 2018, Indonesia[@R92]                      ≥45                    203\                      AHT                                                                                                                                                                                                                    0.95 (0.45 to 1.98)               Unadjusted estimates                                                                                                                                                                                                                                  High
                                                                              61/142                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                   

  Saarti 2016, Beirut[@R39]                            ≥18                    117\                      AHT                                                                                                                                                                                                                    0.50 (0.22 to 1.13)               Unadjusted estimates                                                                                                                                                                                                                                  High
                                                                              59/58                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                    

  Korb-Savoldelli 2012, France[@R127]                  ≥18                    199\                      AHT                                                                                                                                                                                                                    0.86 (0.41 to 1.80)               Unadjusted estimates                                                                                                                                                                                                                                  High
                                                                              114/85                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                   

  Sutar 2017, India[@R146]                             ≥18                    213\                      AHT                                                                                                                                                                                                                    0.80 (0.22 to 2.94)               Unadjusted estimates                                                                                                                                                                                                                                  High
                                                                              96/117                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                   

  Yue 2015, China[@R93]                                Mean age 64.15±10.81   232\                      AHT                                                                                                                                                                                                                    0.99 (0.59 to 1.66)               Unadjusted estimates                                                                                                                                                                                                                                  High
                                                                              110/122                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                  
  ------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

ACEi, ACE inhibitor; AHT, antihypertensive; ARB, angiotensin II receptor blocker; BB, beta-blocker; BMI, body mass index; CCB, calcium channel blocker; CDS, chronic disease score; CV, cardiovascular; GP, general practitioner; MPR, Medication Possession Ratio; n.a, not available; PDC, Proportion of Days Covered.

The majority of the studies considered younger subjects, particularly among the 82 selected studies (1) 42[@R28] were focused on a younger population, (2) 11[@R76] were focused on individuals aged 30 years old or more and (3) 14 papers[@R72] selected older subjects. Conversely, 15[@R46] studies did not specify the age range of enrolled patients.

Regarding the sample size, a great proportion of the studies involved around or less than 500[@R28] or 1000[@R46] individuals. Just two studies[@R66] were based on less than 10 000 subjects, five and four considered, respectively, around or more than 10 000[@R97] or 50 000[@R103] participants, three[@R72] involved about 100 000 subjects and six[@R73] studies were based on 200 000 or more individuals. Just one study[@R104] involved about 30 million of hypertensive subjects. The majority of the studies conducted with the use of MPR/PDC metric considered a wide list of AHT[@R28] and adjustments[@R46] while just 3[@R78] and 11[@R40] were found among those based on questionnaires. The length of follow-up was accounted for studies based on refill rates by mainly considering 1 year of observation,[@R28] while the remaining papers considered less than 1,[@R76] 2o[@R46] or more than 3 years.[@R103] Considering geographical area, 26 studies were conducted respectively in America[@R28] and Asia,[@R73] 15 in the Mediterranean countries,[@R39] 8 in Africa,[@R40] 6 in North Europe[@R46] and just 1 in Australia.[@R96]

Sex--adherence association {#s3-2}
--------------------------

As shown in [figure 2](#F2){ref-type="fig"}, no significant between-sex differences in adherence to AHT were observed, whether all study-specific estimates were summarised (OR~s~ 1.04, 95% CI 1.00 to 1.09, p=0.07), or estimates were pooled according to the metric used for measuring adherence (the OR~s~ ranging between 1.00, 95% CI 0.96 to 1.03, and 1.06, 95% CI 0.95 to 1.18). With the exception of summarised estimates based on MMAS-8 metric, significant between-study heterogeneity was observed with I^2^ values ranging from 90% (MMAS-4) to 99% (PDC). No evidence of influence of any individual study ([online supplementary table S4](#SP1){ref-type="supplementary-material"}) was observed for any summarised estimate.

![Forest plots of study-specific and summary relative risks for adherence to antihypertensive drugs in women compared with men obtained by the following measurements: PDC, MPR, 4-item and 8-item Morisky Medication Scale. Squares represent study-specific relative risk estimates (size of the square reflects the study-specific statistical weight, ie, the inverse of the variance); horizontal lines represent 95% CIs; diamonds represent summary relative risk estimates with corresponding 95% CIs; p values are from testing for heterogeneity between study-specific estimates. Different lengths of follow-up are shown for PDC and MPR measurements. MPR, medication possession ratio; PDC, proportion of days covered.](bmjopen-2019-036418f02){#F2}

Exploring sources of confounding of sex--adherence association {#s3-3}
--------------------------------------------------------------

The effect of selected characteristics of the included studies in modifying the sex--adherence association is shown in [online supplementary table S5](#SP1){ref-type="supplementary-material"}. There was no statistical evidence that men and women differently adhered to AHT therapy (model 1), not even when the effect of the method for collecting adherence data (model 2), the inclusion of incident or prevalent AHT users (model 3), adjustment of the original estimates (model 4), nor the geographical area where the study was conducted (model 5) were taken into account.

Exploring sources of heterogeneity of sex--adherence association {#s3-4}
----------------------------------------------------------------

As shown in [figure 3](#F3){ref-type="fig"}, inconsistent findings were observed among older patients according to the adherence measure: men were more adherent according to the Morisky metric (OR~s~ 0.84, 95% CI 0.72 to 0.97, p=0.02) but this result was not confirmed by the PDC/MPR scale.

![Forest plots of study-specific and summary relative risks for adherence to antihypertensive drugs in women compared with men obtained by MPR and PDC measurements together and Morisky among the elderly population (ie, ≥65 years). Squares represent study-specific relative risk estimates (size of the square reflects the study-specific statistical weight, ie, the inverse of the variance); horizontal lines represent 95% CIs; diamonds represent summary relative risk estimates with corresponding 95% CIs; p values are from testing for heterogeneity between study-specific estimates. Different lengths of follow-up are shown. MPR, Medication Possession Ratio; PDC, Proportion of Days Covered.](bmjopen-2019-036418f03){#F3}

Accordingly, subgroup analyses focusing on patients aged more than 18 years ([online supplementary figure S1](#SP2){ref-type="supplementary-material"}), 1-year length of follow-up ([online supplementary figure S2](#SP3){ref-type="supplementary-material"}), geographical area where the study was performed ([online supplementary figure S3](#SP4){ref-type="supplementary-material"}) and adjusted or unadjusted estimates ([online supplementary figure S4](#SP5){ref-type="supplementary-material"}), never provided convincing evidence that adherence was different between men and women. Furthermore, sex did not show any effect not even stratifying the analysis for prevention status (primary vs secondary) nor for drug users (incident vs prevalent users).
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Discussion {#s4}
==========

The current meta-analysis did not provide convincing evidence that men and women differently adhere to AHT drug therapy. However, although we did not find evidence of influence of any individual study, and almost all the included articles were classified as high-quality studies, inconsistency between studies suggests that sex--adherence association need careful discussion before being judged absent.

Several reasons might explain the between-study heterogeneity for adherence detected by self-report and pharmacy refill metric. A first cause could be due to different methods assessing adherence. Two measurement methods were considered by our meta-analysis, namely self-report and pharmacy refill prescription-based ones. Findings conflicting with the ours were reported by a previous review based on the self-reported 8-item Morisky scale.[@R57] The Morisky scale is a common and validated tool for the adherence screening that has been shown to predict adherence with CV medications.[@R55] However, direct questions about the use of medications could cause the overestimation of adherence that is likely due by the willingness of patients to appear adherent[@R150]; thus, the identification of subjects who forget to take drugs could be difficult. Pharmacy refill metrics (ie, the more diffuse tools for assessing adherence of large population[@R153]) provide highly accurate and inexpensive information about the prescribed treatment.[@R59] However, pharmacy records rarely report data on the prescribed dose. This is an important limitation in our setting since the between-sex difference in drugs dosing is requested according to difference in pharmacokinetics parameters. However, notwithstanding the differences between measurement methods, our meta-analysis did not find that sex affected both self-reported adherence and refill rate.

A second cause of between-study heterogeneity might be due to differences in characteristics of the included patients that may interact with sex and affect drug adherence. To assess if age, prevention status (primary vs secondary), incident/prevalent users and other characteristics could modify the sex--adherence association, stratified analyses were performed. For example, by limiting the analysis to patients older than 65 years, between-study homogeneous estimates were obtained for self-reported based but not for pharmacy-refill based investigations. Moreover, we found that, compared with older women, older men had higher Morisky-based adherence to AHT therapy, while no difference in the refill rate was found. It is possible that the reproducibility of answers to medication-taking questions of the MMAS questionnaire could be different between sex groups among the elderly population, showing better compliance in men and/or worse behaviour among women than what actually is. However, because this remains a speculative and unverified hypothesis, the association between sex and AHT adherence among elderly must be further investigated.

Our meta-analysis did not offer any evidence that men and women from five continents and broad areas (Americas, North Europe, Mediterranean countries, Asia and Africa) differently adhere to AHT drug therapy, thus excluding that between-population cultural differences might explain the observed between-study inconsistency. In addition, we did not find that between-study heterogeneity diminished by limiting the analysis to 1-year adherence, rather than for heterogeneous periods of follow-up, or by stratifying studies on adjusted estimates.

Eligibility and exclusion criteria likely explain between-study heterogeneity. For example, the exclusion of AHT prevalent users (ie, the inclusion of new-user only[@R156]) or the setting for AHT treatment (ie, for primary or secondary prevention of CV disease[@R157]) most likely contribute to explain between-study inconsistency.

A further explanation for between-study inconsistency might be a difference in methods for reducing confounding. Estimates adjusted for the main known confounders of the association of interest were reported from studies based on pharmacy-refill measurement of adherence, while rough estimates were usually reported from self-reports. Characteristics like the level of education, the presence of diabetes or the socioeconomic status may have influenced the pooled estimate. Although the majority of papers adjusted estimates for sociodemographic and economic factors, concomitant medications and comorbidities, just a few of them considered CV risk factors, medical service type and type of AHT drug as the initial treatment strategy. Under these circumstances, we decided to perform a random-effect model to incorporate the heterogeneity due to the wide range of populations studied in the included investigations. Furthermore, we undertook also meta-regression analyses to identify important determinants of heterogeneity. However, there was no evidence that men and women differently adhered to AHT therapy also when some selected characteristics (eg, the inclusion of incident or prevalent AHT users) were taken into account.

Our study has three main limitations. First, although the adjusted estimates with the largest number of confounders were included in our meta-analysis, covariates definition and their distribution could be not sufficiently homogeneous among studies and this may have contributed to the observed heterogeneity.[@R147] Second, language, publication and reporting biases may have affected our findings. However, few studies were excluded because written in other languages than English. In addition, if the studies that found no statistically significant differences had been less published or disseminated, the inclusion of them in our analysis should move the (already not significant) summarised estimate towards the null. Third, we decided to evaluate the information obtained by only self-report and prescription refill metrics. In fact, further methods exist to assess drug adherence,[@R153] such as pill counts, electronic monitoring[@R158] and measurement of plasma or urinary level.[@R160] However, almost all the studies assessing adherence to AHT drugs in biochemical assays involve a population affected by resistant hypertension. Because the aim of our meta-analysis was to synthesise the evidence regarding the sex differences in the adherence to pharmacological treatment among hypertensive patients, we preferred to exclude studies on specific populations. Nevertheless, future systematic reviews on this topic, above all on studies based on adherence methods whose use has dramatically increased in the last years (eg, electronic monitoring), should address this gap.

Conclusions {#s5}
===========

Although, our study offers the most updated estimates on this issue, weak and non-definitive evidence for sex differences in drug adherence were obtained. Therefore, there are no reasons to focus the clinical attention to and introduce policies aimed at specific sex strata. Being poor adherence to chronic drug therapies a ubiquitously issue of public health, our little knowledge about factors affecting adherence, urgently requires high-quality studies investigating this issue. Indeed, further researches carried out by a multidisciplinary team of healthcare professionals could shed light on this critical topic and help decision-makers to develop comprehensive programmes of hypertension management.
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